Key Highlights
● Palatin Technologies has shifted its listing from NYSE American to the Nasdaq Capital Market and is advancing melanocortin receptor (MC4R) obesity candidates alongside its approved drug bremelanotide, while operating with a small cash balance and reliance on partner payments.
● As of March 31, 2026, Palatin reported cash of $10.2 million, down from $14.5 million at December 31, 2025, with fiscal third-quarter revenue of $3.9 million.
● Palatin remains a sub-$20 million market-capitalization company that needed a reverse split to preserve its prior listing and continues to post net losses with modest cash reserves.
● Investors should watch for progress toward the planned 2026-2027 IND filings for the MC4R obesity pipeline.
Palatin Technologies, Inc. (NASDAQ: PTN) completed a move to the Nasdaq Capital Market on May 29, 2026, following approval announced May 18, 2026, with the ticker unchanged at PTN. The switch came roughly nine months after the company executed a 1-for-50 reverse stock split, effective August 8, 2025, to meet listing standards, and after a $18.2 million public offering closed in November 2025 that helped it regain NYSE American compliance in the interim. The exchange change arrives as Palatin, long known for bremelanotide (marketed as Vyleesi for hypoactive sexual desire disorder), pushes newer melanocortin-4 receptor (MC4R) candidates toward the crowded obesity treatment landscape, positioning itself around combination and rare-disease niches rather than head-on GLP-1 competition.
What happened
Palatin's board approved and completed the transfer of its common stock listing from NYSE American to the Nasdaq Capital Market, with trading beginning May 29, 2026. Chief Executive Officer Carl Spana said the move was intended to improve visibility, enhance trading liquidity, and increase exposure to institutional investors, according to the company's press release. No stockholder action was required. The listing change followed a period of balance-sheet repair: the August 2025 reverse split addressed a minimum-bid-price deficiency, and the November 2025 public offering, upsized to $18.2 million with full exercise of the underwriters' over-allotment option, restored NYSE American compliance before the subsequent Nasdaq application. Most recently, on May 13, 2026, Palatin reported fiscal third-quarter 2026 results (quarter ended March 31, 2026), disclosing $3.9 million in collaboration and license revenue, a net loss of $1.4 million ($0.37 per share), and cash of $10.2 million.
Why the development matters
For a micro-cap biotech, an exchange upgrade is more a signaling and mechanical event than an operational catalyst, but it can matter for index eligibility, institutional mandates that restrict NYSE American holdings, and options-market accessibility. It follows directly from Palatin's effort to stabilize its share structure after the reverse split. Separately, and more substantively, Palatin used the ObesityWeek 2025 conference (November 6, 2025) to present preclinical data on its oral MC4R candidate PL7737 and clinical data suggesting that adding a low dose of its approved MC4R agonist bremelanotide to tirzepatide produced greater weight reduction than tirzepatide alone in a Phase 2 study, without new safety signals or added gastrointestinal side effects, and with weight maintenance sustained after tirzepatide was stopped. That combination angle, positioning an MC4R agonist as an adjunct to, rather than a competitor of, GLP-1 drugs, is central to how Palatin is framing its relevance in obesity therapeutics.
Company and product background
Palatin's pipeline centers on melanocortin receptor agonism across several indications. In obesity, it is advancing two MC4R-selective candidates for rare, MC4R-pathway disorders, hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome, rather than general-population obesity. Disclosures show some evolution in specifics: an earlier pipeline description targeted an IND filing for oral candidate PL7737 in the first half of 2026, while the May 2026 earnings release and Nasdaq announcement instead describe a once-weekly injectable peptide targeting an IND in the fourth calendar quarter of 2026, and a next-generation oral molecule built on PL7737 data targeting an IND in the first half of 2027. Investors should treat the oral-program timeline as having shifted rather than assume both descriptions apply. PL7737 carries FDA Orphan Drug Designation for leptin receptor deficiency-related obesity, and preclinical data at ObesityWeek showed dose-dependent weight loss in diet-induced obese mice, no blood pressure effects, and no adverse findings in hERG, Ames, or 28-day rat toxicity testing. Beyond obesity, Palatin has an August 2025 research collaboration with Boehringer Ingelheim for melanocortin receptor-targeted treatments in diabetic retinopathy and diabetic macular edema, carrying potential milestones up to €280 million plus tiered royalties (the upfront amount was not disclosed, though incremental collaboration revenue has since been recognized). It also sublicensed ocular candidate PL9643 (dry eye, following positive Phase 3 data) to Altanispac Labs for a reported $3.8 million upfront in January 2026, and is in active out-licensing talks for PL8177 (ulcerative colitis, positive Phase 2 topline data in early 2025) and an MC4R program in diabetic nephropathy (positive Phase 2 topline data in late 2024).
Financial position
As of March 31, 2026, Palatin reported cash of $10.2 million, down from $14.5 million at December 31, 2025. Fiscal third-quarter revenue was $3.9 million and the nine-month net loss was $4.0 million ($1.63 per share); quarterly operating expenses were roughly $5.5 million ($3.5 million R&D, $2.0 million G&A). Management stated that cash plus expected other receivables (about $2.2 million) should fund operations through June 30, 2027, an estimate, not a guarantee, dependent on continued collaboration revenue. Shares outstanding were approximately 1.78 million following the reverse split, and the November 2025 offering was the company's most recent equity raise. Given the small cash base, further dilution or financing before mid-2027 should not be ruled out.
Bull case
Bulls point to a diversified partnering strategy, Boehringer Ingelheim, Altanispac Labs, and ongoing out-licensing talks for two other assets, that generates non-dilutive revenue while validating the melanocortin receptor platform across multiple disease areas. The bremelanotide-tirzepatide combination data, if replicated in larger trials, could position Palatin as an adjunct-therapy player in obesity without needing to out-compete GLP-1 leaders directly, while orphan-designated PL7737 targets underserved rare obesity populations with less competitive pressure.
Risk case
Palatin remains a sub-$20 million market-capitalization company that needed a reverse split to preserve its prior listing and continues to post net losses, with cash reserves modest relative to typical clinical-stage burn. Its most advanced obesity candidates are preclinical or early-stage, IND timelines have already shifted once, and cash-runway guidance depends on receivables and revenue that are not contractually guaranteed. Historical share-count instability and reliance on episodic licensing deals add uncertainty to any long-term financial projection.
What investors should watch next
1. Whether the once-weekly injectable MC4R candidate files an IND in Q4 calendar 2026 as targeted.
Conclusion
Palatin's Nasdaq transition closes a chapter of listing-compliance repair work that included a steep reverse split and a sizable equity raise within the past year. The more consequential story for investors is whether its melanocortin receptor platform, anchored by early obesity combination data and a diversified set of partnered and preclinical assets, can generate enough non-dilutive revenue and clinical progress to justify its valuation before its estimated cash runway ends in mid-2027. Both the opportunity and the balance-sheet constraints are real, and neither should be read as a directional call on the stock.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.






Please wait processing your request...